Published in Vaccine Weekly, October 23rd, 1995
The collaboration will provide Corixa with significant funding to support its research and development activities aimed at the generation of T-cell active vaccines for infectious disease applications. In exchange for committed, multi-year funding directed toward new vaccine development for a specific disease target, SB will receive options to license Corixa discovered vaccines in exchange for payment to Corixa of license fees, milestone fees (upon successful completion of development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly